PT1874748E - Compostos piperazina ou diaza-cíclicos substituídos com 2-aminocarbonilo moduladores do inibidor da proteína da apoptose (iap) - Google Patents

Compostos piperazina ou diaza-cíclicos substituídos com 2-aminocarbonilo moduladores do inibidor da proteína da apoptose (iap) Download PDF

Info

Publication number
PT1874748E
PT1874748E PT06769822T PT06769822T PT1874748E PT 1874748 E PT1874748 E PT 1874748E PT 06769822 T PT06769822 T PT 06769822T PT 06769822 T PT06769822 T PT 06769822T PT 1874748 E PT1874748 E PT 1874748E
Authority
PT
Portugal
Prior art keywords
iap
diaza
modulators
cyclic compounds
protein inhibitor
Prior art date
Application number
PT06769822T
Other languages
English (en)
Inventor
Robert Eckl
Roswitha Taube
Michael Almstetter
Michael Thormann
Andreas Treml
Christopher Straub
Zhuoliang Chen
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of PT1874748E publication Critical patent/PT1874748E/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/04—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
    • C07D295/18—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carboxylic acids, or sulfur or nitrogen analogues thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
    • C07D295/18—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carboxylic acids, or sulfur or nitrogen analogues thereof
    • C07D295/182—Radicals derived from carboxylic acids
    • C07D295/185—Radicals derived from carboxylic acids from aliphatic carboxylic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/06034—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms
    • C07K5/06052—Val-amino acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0802—Tripeptides with the first amino acid being neutral
    • C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
    • C07K5/0806—Tripeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atoms, i.e. Gly, Ala
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Hematology (AREA)
  • Pulmonology (AREA)
  • Vascular Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Psychology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
PT06769822T 2005-04-13 2006-04-13 Compostos piperazina ou diaza-cíclicos substituídos com 2-aminocarbonilo moduladores do inibidor da proteína da apoptose (iap) PT1874748E (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE102005017116A DE102005017116A1 (de) 2005-04-13 2005-04-13 Hemmstoffe für Inhibitoren von Apoptose Proteinen (IAP)

Publications (1)

Publication Number Publication Date
PT1874748E true PT1874748E (pt) 2009-10-28

Family

ID=36829712

Family Applications (1)

Application Number Title Priority Date Filing Date
PT06769822T PT1874748E (pt) 2005-04-13 2006-04-13 Compostos piperazina ou diaza-cíclicos substituídos com 2-aminocarbonilo moduladores do inibidor da proteína da apoptose (iap)

Country Status (16)

Country Link
US (2) US7932255B2 (pt)
EP (1) EP1874748B1 (pt)
JP (1) JP2008536861A (pt)
KR (1) KR20070119088A (pt)
CN (1) CN101160297B (pt)
AT (1) ATE439355T1 (pt)
AU (1) AU2006236714A1 (pt)
BR (1) BRPI0608783A2 (pt)
CA (1) CA2604821A1 (pt)
DE (2) DE102005017116A1 (pt)
ES (1) ES2328405T3 (pt)
MX (1) MX2007012703A (pt)
PL (1) PL1874748T3 (pt)
PT (1) PT1874748E (pt)
RU (1) RU2007141578A (pt)
WO (1) WO2006113376A1 (pt)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1883627B1 (en) 2005-05-18 2018-04-18 Pharmascience Inc. Bir domain binding compounds
AU2006308453B9 (en) 2005-10-25 2011-12-01 Pharmascience Inc. IAP BIR domain binding compounds
TWI504597B (zh) 2006-03-16 2015-10-21 Pharmascience Inc 結合於細胞凋亡抑制蛋白（ｉａｐ）之桿狀病毒ｉａｐ重複序列（ｂｉｒ）區域之化合物
NZ572836A (en) 2006-05-16 2011-12-22 Pharmascience Inc Iap bir domain binding compounds
US20100317593A1 (en) * 2009-06-12 2010-12-16 Astrazeneca Ab 2,3-dihydro-1h-indene compounds
UY32826A (es) * 2009-08-04 2011-02-28 Takeda Pharmaceutical Compuestos heterocíclicos
SG10201501095WA (en) 2010-02-12 2015-04-29 Pharmascience Inc Iap bir domain binding compounds
BR112013023480B1 (pt) 2011-03-16 2019-10-01 Shanghai Pharmaceuticals Holding Co.,Ltd Composto heterocíclico saturado contendo nitrogênio, seu uso e composição farmacêutica
US10875851B2 (en) 2016-11-18 2020-12-29 Merck Sharp & Dohme Corp. Factor XIIa inhibitors
CN107879997B (zh) * 2017-12-25 2021-01-26 三峡大学 一种小分子抑制剂sld1338及其在制药中的应用
EP3831811A4 (en) 2018-07-31 2022-04-20 Fimecs, Inc. HETEROCYCLIC COMPOUND
EP4006037A4 (en) 2019-07-31 2023-12-13 Fimecs, Inc. HETEROCYCLIC COMPOUND
WO2023215205A1 (en) * 2022-05-06 2023-11-09 Merck Sharp & Dohme Llc Orexin receptor agonists
WO2024107615A1 (en) * 2022-11-17 2024-05-23 Merck Sharp & Dohme Llc Orexin receptor agonists

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL117798A (en) * 1995-04-07 2001-11-25 Schering Plough Corp Tricyclic compounds useful for inhibiting the function of protein - G and for the treatment of malignant diseases, and pharmaceutical preparations containing them
NZ528282A (en) * 1998-03-19 2005-05-27 Vertex Pharma Interleukin-1 beta converting enzyme inhibitors
DE69926078T2 (de) * 1998-12-23 2006-04-20 Schering Corp. Farnesyl-protein transferase inhibitoren
AU2002257114A1 (en) 2001-04-06 2002-10-21 Schering Corporation Treatment of malaria with farsenyl protein transferase inhibitors
US7030141B2 (en) * 2001-11-29 2006-04-18 Christopher Franklin Bigge Inhibitors of factor Xa and other serine proteases involved in the coagulation cascade
US20060128632A1 (en) * 2002-07-02 2006-06-15 Sharma Sushil K Peptide inhibitors of smac protein binding to inhibitor of apoptosis proteins (iap)

Also Published As

Publication number Publication date
KR20070119088A (ko) 2007-12-18
EP1874748B1 (en) 2009-08-12
ES2328405T3 (es) 2009-11-12
ATE439355T1 (de) 2009-08-15
CN101160297B (zh) 2011-07-27
US7932255B2 (en) 2011-04-26
US20110183955A1 (en) 2011-07-28
CA2604821A1 (en) 2006-10-26
BRPI0608783A2 (pt) 2010-01-26
RU2007141578A (ru) 2009-05-20
CN101160297A (zh) 2008-04-09
EP1874748A1 (en) 2008-01-09
PL1874748T3 (pl) 2010-01-29
DE102005017116A1 (de) 2006-10-26
WO2006113376A1 (en) 2006-10-26
DE602006008447D1 (de) 2009-09-24
US20080207630A1 (en) 2008-08-28
AU2006236714A1 (en) 2006-10-26
MX2007012703A (es) 2008-01-14
JP2008536861A (ja) 2008-09-11

Similar Documents

Publication Publication Date Title
MX2007012703A (es) Compuestos de piperazina o diaza-ciclicos sustituidos por 2-amino-carbonilo como moduladores del inhibidor de la proteina de apoptosis (iap).
NO2023022I1 (no) cobimetinib, optionally in any form protected by the basic patent, including harmaceutically acceptable salts and sovates thereof, particularly cobimetinib hemifumarate
EA200900819A1 (ru) Хиназолины для ингибирования pdk1
PT1940839E (pt) Inibidores de piridopirimidinona pi3k alfa
MX2009011211A (es) Indoles sustituidos en la posicion 7 inhibidores de mci-1.
UA98297C2 (en) Triazolopyridazines as tyrosine kinase modulators
MX2009006535A (es) Derivados de indol-4-il-pirimidinil-2-il-amina y su uso como inhibidores de cinasa dependiente de ciclina.
CR7056A (es) Derivados de 3-(4-amidopirrol-2-ilmetilden)-2-indolinona como inhibidores de la protein quinasa
MY149512A (en) Pyrazolylaminopyridine derivatives useful as kinase inhibitors
MY146548A (en) Certain chemicals entities, compositions, and methods
MX2012002542A (es) Compuestos y composiciones como inhibidores de cinasa de proteina.
MX2009004714A (es) Derivados de pirazol fusionado 3-aminocarbonilo sustituidos como moduladores de proteina cinasa.
MY153766A (en) Derivatised proline containing peptide organic compounds as protease inhibitors
EA200801011A1 (ru) Производные пиразина как модуляторы натриевых каналов для лечения боли
MX2008013196A (es) 5-amido-2-carboxiamida-indoles.
WO2008014229A3 (en) Dimeric iap inhibitors
WO2006034391A3 (en) Indole inhibitors of 15-lipoxygenase
MX2010003563A (es) Inhibidores de proteina cinasa de c-met.
TW200738244A (en) 20-Alkyl, gemini vitamin D3 compounds and methods of use thereof
MX2009012079A (es) Compuestos heterociclicos condensados como inhibidores de proteina cinasas.
UA96742C2 (en) Mek inhibitors and use thereof
EA201990219A3 (ru) Ингибиторы mek и способы их применения